Matthew Coffey

3.0k total citations · 1 hit paper
45 papers, 2.1k citations indexed

About

Matthew Coffey is a scholar working on Genetics, Biotechnology and Infectious Diseases. According to data from OpenAlex, Matthew Coffey has authored 45 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Genetics, 27 papers in Biotechnology and 26 papers in Infectious Diseases. Recurrent topics in Matthew Coffey's work include Virus-based gene therapy research (39 papers), Viral gastroenteritis research and epidemiology (26 papers) and Cancer Research and Treatments (26 papers). Matthew Coffey is often cited by papers focused on Virus-based gene therapy research (39 papers), Viral gastroenteritis research and epidemiology (26 papers) and Cancer Research and Treatments (26 papers). Matthew Coffey collaborates with scholars based in United States, United Kingdom and Canada. Matthew Coffey's co-authors include Patrick W.K. Lee, James E. Strong, Peter Forsyth, Alan Melcher, Richard G. Vile, Kensuke Hirasawa, Kara L. Norman, Sandra Nishikawa, Kevin J. Harrington and Elizabeth J. Ilett and has published in prestigious journals such as Science, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Matthew Coffey

44 papers receiving 2.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reovirus Therapy of Tumors with Activated Ras Pathway

1998 626 citations Matthew Coffey, James E. Strong et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Matthew Coffey	1.6k	848	842	781	479	45	2.1k
Phonphimon Wongthida	1.2k 0.7×	866 1.0×	710 0.8×	475 0.6×	162 0.3×	31	1.8k
Katie Twigger	1.1k 0.6×	571 0.7×	399 0.5×	550 0.7×	352 0.7×	18	1.2k
Elena A. Kashentseva	1.7k 1.0×	938 1.1×	1.5k 1.8×	483 0.6×	193 0.4×	53	2.3k
Terry Hermiston	2.7k 1.7×	1.5k 1.7×	2.4k 2.8×	503 0.6×	489 1.0×	61	3.8k
Konstantin Doronin	1.5k 0.9×	741 0.9×	1.2k 1.5×	402 0.5×	251 0.5×	40	1.9k
Christine L. White	691 0.4×	455 0.5×	722 0.9×	381 0.5×	198 0.4×	46	1.9k
Ann E. Tollefson	3.2k 2.0×	1.3k 1.5×	2.6k 3.0×	864 1.1×	364 0.8×	81	4.2k
Ianko Iankov	865 0.5×	501 0.6×	469 0.6×	326 0.4×	141 0.3×	54	1.6k
Johnny Cornelis	1.3k 0.8×	601 0.7×	963 1.1×	669 0.9×	121 0.3×	73	2.0k
Nanhai G. Chen	2.2k 1.3×	1.5k 1.8×	1.3k 1.5×	296 0.4×	858 1.8×	97	3.5k

Countries citing papers authored by Matthew Coffey

Since Specialization

Citations

This map shows the geographic impact of Matthew Coffey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Coffey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Coffey more than expected).

Fields of papers citing papers by Matthew Coffey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Coffey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Coffey. The network helps show where Matthew Coffey may publish in the future.

Co-authorship network of co-authors of Matthew Coffey

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Coffey. A scholar is included among the top collaborators of Matthew Coffey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Coffey. Matthew Coffey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goel, Sanjay, Allyson J. Ocean, Mohammad H. Ghalib, et al.. (2020). Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS -Mutated Colorectal Cancer. Molecular Cancer Therapeutics. 19(5). 1148–1156. 25 indexed citations

Manso, Luís, Patricia Villagrasa, Núria Chic, et al.. (2020). 41P A window-of-opportunity study with atezolizumab and the oncolityc virus pelareorep in early breast cancer (REO-027, AWARE-1). Annals of Oncology. 31. S30–S30. 2 indexed citations

Steele, Lynette P., Aat A. Mulder, Diana J.M. van den Wollenberg, et al.. (2018). Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy. Cancer Immunology Research. 6(10). 1161–1173. 53 indexed citations

Mahalingam, Devalingam, Christos Fountzilas, Jennifer L. Moseley, et al.. (2017). A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. Cancer Chemotherapy and Pharmacology. 79(4). 697–703. 68 indexed citations

Gutierrez, Andres, et al.. (2017). Pooled data analysis of the safety and tolerability of intravenous pelareorep in combination with chemotherapy in 500 + cancer patients. Annals of Oncology. 28. v422–v422. 2 indexed citations

Igase, Masaya, et al.. (2014). The effects of oncolytic reovirus in canine lymphoma cell lines. Veterinary and Comparative Oncology. 14(S1). 61–73. 16 indexed citations

Ocean, Allyson J., Tanios Bekaii‐Saab, Imran Chaudhary, et al.. (2013). A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant KRAS-mutant metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 31(4_suppl). 450–450. 9 indexed citations

Nuovo, Gerard J., Michela Garofalo, Nicola Valeri, et al.. (2012). Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Modern Pathology. 25(10). 1333–1344. 45 indexed citations

Roulstone, Victoria, Katie Twigger, S. Zaidi, et al.. (2012). Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin–paclitaxel doublet chemotherapy. Gene Therapy. 20(5). 521–528. 48 indexed citations

10.

Kelly, Kevin R., Steffan T. Nawrocki, Alain C. Mita, et al.. (2009). Reovirus-based therapy for cancer. Expert Opinion on Biological Therapy. 9(7). 817–830. 54 indexed citations

11.

Ilett, Elizabeth J., Robin Prestwich, Timothy Kottke, et al.. (2009). Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Therapy. 16(5). 689–699. 99 indexed citations

12.

Sei, Shizuko, Kunio Nagashima, Ralph E. Parchment, et al.. (2009). Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Molecular Cancer. 8(1). 47–47. 93 indexed citations

13.

Ghalib, Mohammad H., Kavita Desai, Imran Chaudhary, et al.. (2009). Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors. Investigational New Drugs. 28(5). 641–649. 116 indexed citations

14.

Errington‐Mais, Fiona, Charles L. White, Katie Twigger, et al.. (2008). Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Therapy. 15(18). 1257–1270. 86 indexed citations

15.

Pandha, Hardev, Kevin J. Harrington, David P. Leader, et al.. (2006). A phase I study of reolysin given intravenously to patients with advanced malignancies. Journal of Clinical Oncology. 24(18_suppl). 3064–3064. 7 indexed citations

16.

Wadler, Scott, Bing Yu, Michelle A. Lane, et al.. (2004). 452 The oncolytic reovirus, Reolysin, augments the anticancer effects of cytotoxic agents in vitro against the ras-mutated human colon cancer cell line HCT116. European Journal of Cancer Supplements. 2(8). 135–135. 9 indexed citations

17.

Norman, Kara L., Matthew Coffey, Kensuke Hirasawa, et al.. (2002). Reovirus Oncolysis of Human Breast Cancer. Human Gene Therapy. 13(5). 641–652. 138 indexed citations

18.

Zhao, Yaguang, et al.. (2001). Hsp90 Phosphorylation Is Linked to Its Chaperoning Function. Journal of Biological Chemistry. 276(35). 32822–32827. 88 indexed citations

19.

Coffey, Matthew, et al.. (1998). Active Participation of Hsp90 in the Biogenesis of the Trimeric Reovirus Cell Attachment Protein ς1. Journal of Biological Chemistry. 273(24). 15227–15233. 19 indexed citations

20.

Leone, Gustavo, et al.. (1996). C-terminal Trimerization, but Not N-terminal Trimerization, of the Reovirus Cell Attachment Protein Is a Posttranslational and Hsp70/ATP-dependent Process. Journal of Biological Chemistry. 271(14). 8466–8471. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact